HK1143418A1 - Metabolomic profiling of prostate cancer - Google Patents

Metabolomic profiling of prostate cancer

Info

Publication number
HK1143418A1
HK1143418A1 HK10110005.0A HK10110005A HK1143418A1 HK 1143418 A1 HK1143418 A1 HK 1143418A1 HK 10110005 A HK10110005 A HK 10110005A HK 1143418 A1 HK1143418 A1 HK 1143418A1
Authority
HK
Hong Kong
Prior art keywords
prostate cancer
metabolomic profiling
metabolomic
profiling
prostate
Prior art date
Application number
HK10110005.0A
Other languages
English (en)
Inventor
Arul M Chinnaiyan
Arun Sreekumar
Matthew W Mitchell
Kay A Lawton
Alvin Berger
Christopher Beecher
Original Assignee
Univ Michigan
Metabolon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Metabolon Inc filed Critical Univ Michigan
Publication of HK1143418A1 publication Critical patent/HK1143418A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
HK10110005.0A 2007-08-16 2010-10-22 Metabolomic profiling of prostate cancer HK1143418A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95623907P 2007-08-16 2007-08-16
US7554008P 2008-06-25 2008-06-25
US13327908P 2008-06-27 2008-06-27
PCT/US2008/073318 WO2009026152A1 (en) 2007-08-16 2008-08-15 Metabolomic profiling of prostate cancer

Publications (1)

Publication Number Publication Date
HK1143418A1 true HK1143418A1 (en) 2010-12-31

Family

ID=40363136

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10110005.0A HK1143418A1 (en) 2007-08-16 2010-10-22 Metabolomic profiling of prostate cancer

Country Status (7)

Country Link
US (1) US20090047269A1 (ja)
EP (2) EP2179292B1 (ja)
JP (2) JP5406187B2 (ja)
AU (1) AU2008289172B2 (ja)
CA (1) CA2695674A1 (ja)
HK (1) HK1143418A1 (ja)
WO (1) WO2009026152A1 (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2662655A1 (en) 2006-09-19 2008-03-27 Metabolon, Inc. Biomarkers for prostate cancer and methods using the same
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
CN104330571B (zh) * 2008-06-20 2017-09-08 味之素株式会社 前列腺疾病的评价方法
PL2438445T3 (pl) * 2009-06-04 2014-12-31 Metanomics Health Gmbh Sposoby diagnozowania raków gruczołu krokowego
WO2011046597A2 (en) * 2009-10-13 2011-04-21 Purdue Research Foundtion Biomarkers for the detection of breast cancer
CN102597762B (zh) * 2009-10-30 2016-08-03 学校法人庆应义塾 抗癌剂感受性判定标记
US20110151497A1 (en) * 2009-12-22 2011-06-23 The Regents Of The University Of Michigan Metabolomic profiling of prostate cancer
US20130023436A1 (en) * 2010-01-15 2013-01-24 Bryan William Jones Disease diagnosis and treatment using computational molecular phenotyping
EP2354794A1 (en) 2010-01-29 2011-08-10 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Diagnosing prostate cancer relapse
JP2011247869A (ja) * 2010-04-27 2011-12-08 Kobe Univ メタボローム解析手法を用いた特定疾患の検査方法
US8980548B2 (en) 2010-05-19 2015-03-17 Metabolon, Inc. Methods and reagents for metabolomics and histology in a biological sample and a kit for the same
US20130217647A1 (en) * 2010-07-28 2013-08-22 Metabolon, Inc. Biomarkers for Prostate Cancer and Methods Using the Same
JP2015518152A (ja) * 2012-04-27 2015-06-25 イースタン バージニア メディカル スクール 前立腺がんの検出用バイオマーカーの定量
US20150310169A1 (en) * 2012-11-09 2015-10-29 Dana-Farber Cancer Institute, Inc. Metabolic profiling in tissue and serum is indicative of tumor differentiation in prostate cancer
WO2014089431A1 (en) * 2012-12-06 2014-06-12 Dana-Farber Cancer Institute, Inc. Metabolomic profiling defines oncogenes driving prostate tumors
KR101462206B1 (ko) * 2013-06-26 2014-11-20 한국과학기술연구원 트립토판 대사 변화를 이용한 위암 진단용 기초 정보 제공 방법
JP6222629B2 (ja) * 2013-08-29 2017-11-01 花王株式会社 排尿障害のバイオマーカー
KR101838133B1 (ko) 2013-10-04 2018-03-14 주식회사 씨스퀘어 사르코신 대사산물 중 포름알데히드를 이용한 전립선암 진단 시험지, 그 제조 방법 및 이를 이용한 전립선암 진단에 필요한 정보를 제공하는 방법
CN105555962A (zh) * 2013-10-04 2016-05-04 Csquare株式会社 利用肌氨酸代谢产物中的甲醛或过氧化物的前列腺癌诊断试纸，其制造方法及利用其的前列腺癌诊断方法
GB201408875D0 (en) 2014-05-19 2014-07-02 Cambridge Oncometrix Ltd Diagnostic method
EP3465202B1 (en) * 2016-06-02 2023-07-05 Metabolon, Inc. Mass spectrometry method for detection and quantitation of metabolites
US20180024132A1 (en) 2016-07-07 2018-01-25 Berg Llc Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer
KR101962882B1 (ko) 2017-06-01 2019-03-28 한국과학기술연구원 구연산염 검출 센서 및 이를 이용한 구연산염 검출 방법
WO2021138611A2 (en) * 2020-01-03 2021-07-08 Femtera Laboratories Reliable metabolite biomarkers for multiple urological cancers
EP4100541A4 (en) * 2020-02-05 2024-05-22 The Cleveland Clinic Foundation DISEASE DETECTION AND TREATMENT BASED ON PHENYLACETYL GLUTAMINES
CN113804901B (zh) * 2020-06-15 2023-06-23 南京市口腔医院 用于口腔鳞癌早期无创诊断的血清脂质标志物及其应用
KR102379017B1 (ko) * 2020-08-18 2022-03-28 서울대학교 산학협력단 13c 또는 2h 동위원소로 표지된 글라이신을 유효성분으로 포함하는 간암 진단용 조성물
CN113440533B (zh) * 2021-07-01 2022-02-01 江南大学 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用
CN115184478A (zh) * 2022-04-26 2022-10-14 沈阳药科大学 一种基于“纤维内衍生化”策略的血浆中70种氨基类物质的定量分析方法及其用途

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
DE3790229D2 (en) * 1986-04-28 1988-08-25 Boehringer Mannheim Gmbh Process and reagent for detecting heart lesions or diseases
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5705188A (en) 1993-02-19 1998-01-06 Nippon Shinyaku Company, Ltd. Drug composition containing nucleic acid copolymer
JP3816518B2 (ja) 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
CA2203809C (en) 1994-10-28 2008-06-03 James M. Wilson Recombinant adenovirus and methods of use thereof
US5872154A (en) 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US6019978A (en) 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
CA2222140C (en) 1995-06-15 2010-11-23 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5854206A (en) 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
WO1997033909A2 (en) 1996-03-15 1997-09-18 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
NZ337446A (en) 1997-02-25 2001-02-23 Corixa Corp Immunogenic portions of a prostate protein and their use in immunotherapy of prostate cancer and methods for their use
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6080912A (en) 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
ES2402947T3 (es) 1997-04-10 2013-05-10 Stichting Katholieke Universiteit University Medical Centre Nijmegen PCA3, genes PCA3 y métodos de uso
US5830730A (en) 1997-05-08 1998-11-03 The Regents Of The University Of California Enhanced adenovirus-assisted transfection composition and method
WO1999002685A1 (en) 1997-07-11 1999-01-21 Introgene B.V. Interleukin-3 gene therapy for cancer
US5972639A (en) 1997-07-24 1999-10-26 Irori Fluorescence-based assays for measuring cell proliferation
US6300136B1 (en) * 1997-09-03 2001-10-09 The Trustees Of The University Of Pennsylvania Methods for diagnosis and treatment of tumors in humans
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
EP1109896A4 (en) 1998-08-14 2005-11-02 Aventis Pharm Prod Inc ADENOVIRUS FORMULATIONS FOR GENE THERAPY
HUP0200073A3 (en) 1998-08-27 2003-12-29 Aventis Pharma Sa Targeted adenovirus vectors for delivery of heterologous genes
US6828429B1 (en) 1999-03-26 2004-12-07 Henry M. Jackson Foundation For The Advancement Of Military Medicine Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer
AU2001262943A1 (en) * 2000-04-14 2001-10-30 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US7329489B2 (en) * 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2001098754A1 (en) 2000-06-22 2001-12-27 Atto Instruments Llc High efficiency cell analysis system and high throughput drug screening system
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20030134677A1 (en) * 2001-09-27 2003-07-17 Salah Obied Method and apparatus for generating real-time embedded software for a chance game
JP2007508384A (ja) * 2003-10-16 2007-04-05 ジ・アドミニストレーターズ・オブ・ザ・トウレーン・エデユケーシヨナル・フアンド 癌を処置するための方法および組成物
JP2005162714A (ja) * 2003-12-05 2005-06-23 Shoken Seika Kagi Kofun Yugenkoshi グリシンｎメチルトランスフェラーゼモノクローナル抗体およびその使用方法
US20060010505A1 (en) 2004-06-18 2006-01-12 Washington University High throughput cancer pharmaceutical screening using drosophila
US20070055456A1 (en) * 2005-08-31 2007-03-08 Daniel Raftery NMR method for differentiating complex mixtures
CA2662655A1 (en) * 2006-09-19 2008-03-27 Metabolon, Inc. Biomarkers for prostate cancer and methods using the same

Also Published As

Publication number Publication date
US20090047269A1 (en) 2009-02-19
EP2179292B1 (en) 2012-11-28
JP5406187B2 (ja) 2014-02-05
EP2597464A2 (en) 2013-05-29
JP2014041154A (ja) 2014-03-06
JP2010537170A (ja) 2010-12-02
EP2597464A3 (en) 2013-07-31
AU2008289172B2 (en) 2013-01-17
EP2179292A4 (en) 2010-08-25
EP2179292A1 (en) 2010-04-28
AU2008289172A1 (en) 2009-02-26
EP2597464B1 (en) 2015-02-25
CA2695674A1 (en) 2009-02-26
WO2009026152A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
HK1143418A1 (en) Metabolomic profiling of prostate cancer
EP2517022A4 (en) METABOLOMIC PROFILING OF PROSTATE CANCER
HRP20181385T1 (hr) Ciljanje abcb5 za terapiju raka
EP2197533A4 (en) ABLATION OF PROSTATE CANCER
IL190382A0 (en) Detecting prostate cancer
IL204541A0 (en) Use of mva to treat prostate cancer
ZA201201107B (en) Cancer metastasis inhibitor
IL212905A0 (en) Individualized cancer dignosis
GB0625321D0 (en) Cancer biomarker
ZA200807934B (en) Cancer treatments
HK1151734A1 (en) Therapeutic for hepatic cancer
EP2310006A4 (en) TREATMENT OF CANCER
BR112012002797A2 (pt) tratamento de câncer de próstata
IL200197A0 (en) Genetic variants contributing to risk of prostate cancer
EP2316033A4 (en) DETECTION OF PROSTATE CANCER USING GLYCOSYLATION PATTERNS OF A SPECIFIC PROSTATIC ANTIGEN (PSA)
IL186980A0 (en) Characterizing prostate cancer
GB0804496D0 (en) Treating cancer
EP2345415A4 (en) THERAPEUTIC / PROPHYLACTIC AGENT FOR PROSTATE CANCER
EP2252706A4 (en) SLIT2-CANCER MARKER
IL211016A0 (en) Prostate cancer methylation assay
EP2501845A4 (en) KREBSBIOMARKER
GB201004304D0 (en) Biomarkers for prostate cancer
AU2008900560A0 (en) Prostate cancer biomarkers
ZA200906095B (en) Genetic variants contributing to risk of prostate cancer
GB0822018D0 (en) Prevention of metastatic cancer